Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
82%
B Cell
32%
microRNA 155
30%
Clustered Regularly Interspaced Short Palindromic Repeat
28%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
28%
Rituximab
21%
Vincristine
20%
microRNA
18%
Neoplasm
18%
International Prognostic Index
15%
Biological Marker
14%
Multiple Myeloma
14%
Programmed Cell Death
14%
Protein Tyrosine Kinase
14%
Cancer
14%
Mediator
14%
Cas9
14%
DNA Damage Response
14%
Cisplatin
14%
Diagnosis
11%
CD20
10%
Malignant Neoplasm
8%
Cyclophosphamide
8%
Doxorubicin
7%
B Lymphocyte Receptor
7%
Gene Expression
6%
Personalized Medicine
6%
Biopsy
6%
Prednisone
5%
Germinal Center
5%
Immunology and Microbiology
B Cell
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
38%
Rituximab
32%
Clustered Regularly Interspaced Short Palindromic Repeat
17%
CXCR4
14%
Cell Death
14%
Mediator
14%
CRISPR/Cas9
14%
Cell Proliferation
14%
B Cell Lymphoma Cell
8%
Diffuse Large B-Cell Lymphoma Cell Line
6%
B-Cell Receptor
6%
Germinal Center
5%
CD20
5%
Cell Line
5%
Keyphrases
Notch3
14%
Hsp90 Inhibitor
14%
Vincristine-induced Neuropathy
14%
Bendamustine
14%
B-cell Linker
14%
Bruton's Tyrosine Kinase
14%
Linker Peptide
14%
CRISPR Interference (CRISPRi)
14%
Molecular Classification
14%
CRISPR-Cas9 Knockout
14%
Cisplatin Response
14%
Knockout Screen
14%
Evolutionary Events
14%
CDCA2
14%
17-AAG
11%
Neuropathy Disability Score
10%
Long-term Remission
9%
ERCC6
6%
